EMA Authorised: Lemtrada (alemtuzumab) — Sanofi Belgium

View source ↗

Summary

The EMA has authorised Lemtrada (alemtuzumab) for the treatment of multiple sclerosis, with a decision date of 27 October 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Lemtrada (alemtuzumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Sanofi Belgium. Decision date: 27/10/2025